Small Pharma Inc.

Small Pharma's Q2 2023 Financial Results, 'Ultra Short-Acting Psychedelic Program' Underway

Small Pharma Inc. (OTCQB: DMTTF), a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six months ended August 31, 2022. For the period numbers show:

Small Pharma Receives European Patent Of Ketamine-Based Compounds For Treatment of Depressive Disorders

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a neuropharmaceutical company focused on psychedelic-assisted therapies, announced on Tuesday, that it has received a European patent that grants protections for certain oral dosage forms of 2R,6R-hydroxynorketamine (“6-HNK”) based c